510(k) device
Nerivio
Theranica Bio-Electronics, Ltd. · Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT, Class II) · First FDA decision Oct 23, 2020, newest May 14, 2025Migraine and headache
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
27
Naming "Nerivio"
MAUDE reports
6
Brand "Nerivio", since 2015
PubMed studies
29
Mentioning "Nerivio"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Nerivio
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K250405 · Decided May 14, 2025 · 90 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio; NerivioInfinity510(k)
K241756 · Decided Oct 8, 2024 · 112 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio510(k)
K201824 · Decided Oct 23, 2020 · 114 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Nerivio", any status and sponsor, newest update first.
- An Open Label Study Assessing REN Treatment in Headache Management in Temporomandibular DisordersRecruiting
TheranicaNot on our public-company list
NCT07639944 · 100 participants (planned) · Start May 4, 2026 · Primary completion Jun 1, 2027
Device: Nerivio treatment · For: Temporomandibular Disorder; Orofacial Pain
Sites: Newark, Delaware; Ridgeland, Mississippi; Commack, New York · 4 sites in all
- The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and FibromyalgiaPivotal-lookingRecruiting
TheranicaNot on our public-company list
NCT07841509 · 120 participants (planned) · Start Jun 23, 2026 · Primary completion Aug 1, 2027
Device: Remote Electrical Neuromodulation (REN) device · For: Migraine; Fibromyalgia; Conditioned Pain Modulation
Sites: Bridgewater, New Jersey; Haifa, Israel
TheranicaNot on our public-company list
NCT07487701 · 332 participants · Start Feb 20, 2026 · Primary completion Apr 15, 2026
Device: Nerivio REN device · For: Migraine
Sites: Bridgewater, New Jersey
24 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Nerivio", and for the whole product code for context.
This brand
6 reports: 3 malfunction, 2 injury, 0 death
Whole product code QGT
7 reports: 3 malfunction, 3 injury, 0 death
Newest reports for this brand
- Nerivio Arm BandOther
MW6004235 · Received Oct 20, 2026 · Event dated Oct 13, 2026
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT)
Device problem as coded: Application Program Problem; Therapeutic or Diagnostic Output Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- NERIVIO INFINITYMalfunction
24778455 · Received Apr 3, 2026 · Event dated Mar 19, 2026
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- NERIVIO INFINITYMalfunction
THERANICA BIO-ELECTRONICS LTD.
MW5185800 · Received Mar 25, 2026 · Event dated Mar 17, 2026
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Nerivio Infinity. Model/Catalog Number: FGD000100. Software Version: FW Version 4.1.2.0, App version 7.28.0.11Open, Classified
Z-2855-2026 · Started Mar 23, 2026 · Posted by FDA Jul 31, 2026
Reason given: Potential for the batter to have a thermal-runway event during charging, resulting in smoke and odor.
Cause as FDA categorized it: Component design/selection · Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT)
Published research
The most relevant PubMed records for "Nerivio"[tiab]. The summary above synthesizes these.
- Drugs for migraine.
Med Lett Drugs Ther · 2023
- Drugs for Migraine.
Med Lett Drugs Ther · 2020
- The Real-World Evaluation of Remote Electrical Neuromodulation in Pediatric Migraines: A Preliminary Study.
Blumovich A, Gerson T, Connelly M, et al. · Children (Basel) · 2025
- Nerivio® remote electrical neuromodulation for acute treatment of chronic migraine.
Nierenburg H, Stark-Inbar A · Pain Manag · 2022Review
- Drugs for prevention of migraine.
Med Lett Drugs Ther · 2026
- One-Year Consistent Safety, Utilization, and Efficacy Assessment of Remote Electrical Neuromodulation (REN) for Migraine Treatment.
Synowiec A, Stark-Inbar A, Weinstein M, et al. · Adv Ther · 2024Research Support, Non-U.S. Gov't
- International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.
Yuan H, Orr SL, Al-Karagholi MAM, et al. · Cephalalgia · 2025Systematic Review, Practice Guideline
- Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.
Ailani J, Rabany L, Tamir S, et al. · Front Pain Res (Lausanne) · 2021
- Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older.
Babaei M, Rapoport AM · Expert Rev Med Devices · 2023
- Acute Treatment of Migraine in Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN).
Esparham A, Stark-Inbar A, Jekel L, et al. · Pediatr Neurol · 2023
- Acute treatment of migraine in children aged 6-11: Real-world analysis of remote electrical neuromodulation (REN).
Werner K, Gerson T, Stark-Inbar A, et al. · Ann Child Neurol Soc · 2024
- Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine.
Tepper SJ, Lin T, Montal T, et al. · Pain Med · 2020
Other devices of this type
Also filed under product code QGT.
- NerivioInfinityTheranica Bioelectronics , Ltd. · 510(k) 2023
- NerivioTheranica Bioelectronics , Ltd. · 510(k) 2023
- Nerivio, FGD000075-4.7Theranica Bioelectronics , Ltd. · 510(k) 2021
- Nerivio MigraTheranica Bioelectronics , Ltd. · De Novo 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.